These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 6633672)
1. The deamination of noradrenaline and 5-hydroxytryptamine by rat brain and heart monoamine oxidase and their inhibition by cimoxatone, toloxatone and MD 770222. Strolin Benedetti M; Boucher T; Fowler CJ Naunyn Schmiedebergs Arch Pharmacol; 1983 Aug; 323(4):315-20. PubMed ID: 6633672 [TBL] [Abstract][Full Text] [Related]
2. The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone. Fowler CJ; Benedetti MS J Neurochem; 1983 Jun; 40(6):1534-41. PubMed ID: 6406646 [TBL] [Abstract][Full Text] [Related]
3. Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Benedetti MS; Boucher T; Carlsson A; Fowler CJ Biochem Pharmacol; 1983 Jan; 32(1):47-52. PubMed ID: 6830619 [TBL] [Abstract][Full Text] [Related]
4. Cimoxatone is a reversible tight-binding inhibitor of the A form of rat brain monoamine oxidase. Fowler CJ; Strolin Benedetti M J Neurochem; 1983 Feb; 40(2):510-3. PubMed ID: 6822834 [TBL] [Abstract][Full Text] [Related]
5. A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain. Fagervall I; Ross SB J Neurochem; 1986 Aug; 47(2):569-76. PubMed ID: 3734795 [TBL] [Abstract][Full Text] [Related]
6. Estimation of the elimination half-life of the monoamine oxidase inhibitor cimoxatone in rat brain on the basis of ex vivo inhibition data. Fowler CJ; Strolin Benedetti M; Rovei V Eur J Drug Metab Pharmacokinet; 1983; 8(4):389-93. PubMed ID: 6673976 [TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of the A form of monoamine oxidase by 4-dimethylamino-alpha-methylphenylalkylamine derivatives in the rat. Ask AL; Hellström W; Norrman S; Ogren SO; Ross SB Neuropharmacology; 1982 Apr; 21(4):299-308. PubMed ID: 7088264 [TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase inhibition and brain amine metabolism after oral treatment with toloxatone in the rat. Keane PE; Kan JP; Sontag N; Benedetti MS J Pharm Pharmacol; 1979 Nov; 31(11):752-4. PubMed ID: 41906 [TBL] [Abstract][Full Text] [Related]
9. Characteristics of the inhibition of rat brain monoamine oxidase in vitro by MD780515. Kan JP; Strolin Benedetti M J Neurochem; 1981 Apr; 36(4):1561-71. PubMed ID: 7264651 [TBL] [Abstract][Full Text] [Related]
10. Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain. Fowler CJ; Tipton KF J Neurochem; 1982 Mar; 38(3):733-6. PubMed ID: 7057191 [TBL] [Abstract][Full Text] [Related]
11. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Green AR; Mitchell BD; Tordoff AF; Youdim MB Br J Pharmacol; 1977 Jul; 60(3):343-9. PubMed ID: 890205 [No Abstract] [Full Text] [Related]
12. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Berlin I; Zimmer R; Thiede HM; Payan C; Hergueta T; Robin L; Puech AJ Br J Clin Pharmacol; 1990 Dec; 30(6):805-16. PubMed ID: 1705137 [TBL] [Abstract][Full Text] [Related]
13. [Effect of benzamide derivatives on rat brain monoamine oxidase activity in vitro]. Gol'dina OA; Zagorevskiĭ VA; Lopatina KI; Sokolova TV; Gankina EM Biull Eksp Biol Med; 1986 Aug; 102(8):170-2. PubMed ID: 3742029 [TBL] [Abstract][Full Text] [Related]
14. Differential substrate specificity of monoamine oxidase in the rat heart and renal cortex. Guimarães JT; Vindis C; Soares-da-Silva P; Parini A Life Sci; 2003 Jul; 73(8):955-67. PubMed ID: 12818349 [TBL] [Abstract][Full Text] [Related]
15. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile. Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694 [TBL] [Abstract][Full Text] [Related]
16. Effect of selective monoamine oxidase inhibitors on rat brain mitochondrial monoamine oxidase during hyperbaric oxygenation. Goroshinskaya IA; Bronovizkaya ZG; Gorkin VZ Commun Psychopharmacol; 1977; 1(1):39-47. PubMed ID: 606471 [No Abstract] [Full Text] [Related]
17. Unusual pattern of beta-phenylethylamine deamination in the rat heart. Tiago Guimarães J; Soares-da-Silva P Neurobiology (Bp); 2000; 8(1):109-18. PubMed ID: 11008882 [TBL] [Abstract][Full Text] [Related]
18. The enzyme-activated irreversible inhibition of type-B monoamine oxidase by 3-(4-[(3-chlorophenyl)methoxy]phenyl)-5-[(methylamino) methyl]-2-oxazolidinone methanesulphonate (compound MD 780236) and the enzyme-catalysed oxidation of this compound as competing reactions. Tipton KF; Fowler CJ; McCrodden JM; Strolin Benedetti M Biochem J; 1983 Jan; 209(1):235-42. PubMed ID: 6847610 [TBL] [Abstract][Full Text] [Related]
19. [Inhibition of noradrenaline deamination by antidepressants]. Moskvitina TA; Gankina EM; Val'dman AV Biull Eksp Biol Med; 1986 Jul; 102(7):44-6. PubMed ID: 3730591 [TBL] [Abstract][Full Text] [Related]
20. Antagonism between long acting monoamine oxidase inhibitors (MAOI) and MD780515, a new specific and reversible MAOI. Kan JP; Benedetti MS Life Sci; 1980 Jun; 26(25):2165-71. PubMed ID: 7401915 [No Abstract] [Full Text] [Related] [Next] [New Search]